The assumption that early-onset and late-onset Alzheimer's disease share identical genetic underpinnings faces significant challenge from new evidence revealing distinct pathological pathways. This finding could reshape screening strategies and therapeutic development for the 200,000 Americans diagnosed with early-onset disease before age 65.
Analysis of genetic risk scores from two major cohort studies—the Longitudinal Early-onset Alzheimer's Disease Study and the Alzheimer's Disease Neuroimaging Initiative—demonstrates that polygenic markers predicting late-onset disease fail to accurately predict early-onset cases. While both disease forms showed elevated polygenic risk scores compared to healthy controls, these genetic markers neither predicted early-onset disease risk independent of APOE ε4 status nor correlated with age of symptom onset or cognitive decline severity.
The disconnect becomes more intriguing when examining biomarker patterns. Higher polygenic risk scores in early-onset patients correlated with elevated SNAP-25 levels, a synaptic protein indicating neuronal damage, alongside paradoxically lower brain amyloid deposits measured through PET imaging and cerebrospinal fluid analysis. This unexpected biomarker profile suggests early-onset disease may involve distinct mechanisms of neurodegeneration that bypass traditional amyloid accumulation patterns seen in late-onset cases. The research underscores growing recognition that Alzheimer's represents multiple disease entities rather than a single condition with varying onset timing. For clinicians, these findings highlight limitations of current genetic risk assessments when counseling younger patients with family histories. The distinct pathophysiology also suggests that therapeutic strategies effective for late-onset disease may require modification for early-onset cases, potentially explaining mixed results in clinical trials that combine both populations.